Robert C Grant1, Iris Selander2, Ashton A Connor3, Shamini Selvarajah4, Ayelet Borgida2, Laurent Briollais2, Gloria M Petersen5, Jordan Lerner-Ellis6, Spring Holter2, Steven Gallinger7. 1. Ontario Institute for Cancer Research, Canada; Department of Medicine, University of Toronto, Canada. 2. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Canada. 3. Division of General Surgery, Department of Surgery, University Health Network, University of Toronto, Canada. 4. Laboratory Medicine and Pathobiology, University of Toronto, Canada. 5. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 6. Ontario Institute for Cancer Research, Canada; Laboratory Medicine and Pathobiology, University of Toronto, Canada; Pathology and Laboratory Medicine, Mount Sinai Hospital, Canada. 7. Ontario Institute for Cancer Research, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Canada; Division of General Surgery, Department of Surgery, University Health Network, University of Toronto, Canada. Electronic address: steven.gallinger@uhn.on.ca.
Abstract
BACKGROUND & AIMS: We investigated the prevalence of germline mutations in APC, ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, PRSS1, STK11, and TP53 in patients with pancreatic cancer. METHODS: The Ontario Pancreas Cancer Study enrolls consenting participants with pancreatic cancer from a province-wide electronic pathology database; 708 probands were enrolled from April 2003 through August 2012. To improve the precision of BRCA2 prevalence estimates, 290 probands were selected from 3 strata, based on family history of breast and/or ovarian cancer, pancreatic cancer, or neither. Germline DNA was analyzed by next-generation sequencing using a custom multiple-gene panel. Mutation prevalence estimates were calculated from the sample for the entire cohort. RESULTS: Eleven pathogenic mutations were identified: 3 in ATM, 1 in BRCA1, 2 in BRCA2, 1 in MLH1, 2 in MSH2, 1 in MSH6, and 1 in TP53. The prevalence of mutations in all 13 genes was 3.8% (95% confidence interval, 2.1%-5.6%). Carrier status was associated significantly with breast cancer in the proband or first-degree relative (P < .01), and with colorectal cancer in the proband or first-degree relative (P < .01), but not family history of pancreatic cancer, age at diagnosis, or stage at diagnosis. Of patients with a personal or family history of breast and colorectal cancer, 10.7% (95% confidence interval, 4.4%-17.0%) and 11.1% (95% confidence interval, 3.0%-19.1%) carried pathogenic mutations, respectively. CONCLUSIONS: A small but clinically important proportion of pancreatic cancer is associated with mutations in known predisposition genes. The heterogeneity of mutations identified in this study shows the value of using a multiple-gene panel in pancreatic cancer.
BACKGROUND & AIMS: We investigated the prevalence of germline mutations in APC, ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, PRSS1, STK11, and TP53 in patients with pancreatic cancer. METHODS: The Ontario Pancreas Cancer Study enrolls consenting participants with pancreatic cancer from a province-wide electronic pathology database; 708 probands were enrolled from April 2003 through August 2012. To improve the precision of BRCA2 prevalence estimates, 290 probands were selected from 3 strata, based on family history of breast and/or ovarian cancer, pancreatic cancer, or neither. Germline DNA was analyzed by next-generation sequencing using a custom multiple-gene panel. Mutation prevalence estimates were calculated from the sample for the entire cohort. RESULTS: Eleven pathogenic mutations were identified: 3 in ATM, 1 in BRCA1, 2 in BRCA2, 1 in MLH1, 2 in MSH2, 1 in MSH6, and 1 in TP53. The prevalence of mutations in all 13 genes was 3.8% (95% confidence interval, 2.1%-5.6%). Carrier status was associated significantly with breast cancer in the proband or first-degree relative (P < .01), and with colorectal cancer in the proband or first-degree relative (P < .01), but not family history of pancreatic cancer, age at diagnosis, or stage at diagnosis. Of patients with a personal or family history of breast and colorectal cancer, 10.7% (95% confidence interval, 4.4%-17.0%) and 11.1% (95% confidence interval, 3.0%-19.1%) carried pathogenic mutations, respectively. CONCLUSIONS: A small but clinically important proportion of pancreatic cancer is associated with mutations in known predisposition genes. The heterogeneity of mutations identified in this study shows the value of using a multiple-gene panel in pancreatic cancer.
Authors: H Ozçelik; B Schmocker; N Di Nicola; X H Shi; B Langer; M Moore; B R Taylor; S A Narod; G Darlington; I L Andrulis; S Gallinger; M Redston Journal: Nat Genet Date: 1997-05 Impact factor: 38.330
Authors: A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton Journal: Am J Hum Genet Date: 2003-04-03 Impact factor: 11.025
Authors: M Goggins; M Schutte; J Lu; C A Moskaluk; C L Weinstein; G M Petersen; C J Yeo; C E Jackson; H T Lynch; R H Hruban; S E Kern Journal: Cancer Res Date: 1996-12-01 Impact factor: 12.701
Authors: L C Hartmann; T A Sellers; D J Schaid; T S Frank; C L Soderberg; D L Sitta; M H Frost; C S Grant; J H Donohue; J E Woods; S K McDonnell; C W Vockley; A Deffenbaugh; F J Couch; R B Jenkins Journal: J Natl Cancer Inst Date: 2001-11-07 Impact factor: 13.506
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Kathleen M Murphy; Kieran A Brune; Constance Griffin; Jennifer E Sollenberger; Gloria M Petersen; Ravi Bansal; Ralph H Hruban; Scott E Kern Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Hans F A Vasen; Ignacio Blanco; Katja Aktan-Collan; Jessica P Gopie; Angel Alonso; Stefan Aretz; Inge Bernstein; Lucio Bertario; John Burn; Gabriel Capella; Chrystelle Colas; Christoph Engel; Ian M Frayling; Maurizio Genuardi; Karl Heinimann; Frederik J Hes; Shirley V Hodgson; John A Karagiannis; Fiona Lalloo; Annika Lindblom; Jukka-Pekka Mecklin; Pal Møller; Torben Myrhoj; Fokko M Nagengast; Yann Parc; Maurizio Ponz de Leon; Laura Renkonen-Sinisalo; Julian R Sampson; Astrid Stormorken; Rolf H Sijmons; Sabine Tejpar; Huw J W Thomas; Nils Rahner; Juul T Wijnen; Heikki Juhani Järvinen; Gabriela Möslein Journal: Gut Date: 2013-02-13 Impact factor: 23.059
Authors: Carmen Radecki Breitkopf; Gloria M Petersen; Susan M Wolf; Kari G Chaffee; Marguerite E Robinson; Deborah R Gordon; Noralane M Lindor; Barbara A Koenig Journal: J Law Med Ethics Date: 2015 Impact factor: 1.718
Authors: Michael Skaro; Neha Nanda; Christian Gauthier; Matthäus Felsenstein; Zhengdong Jiang; Miaozhen Qiu; Koji Shindo; Jun Yu; Danielle Hutchings; Ammar A Javed; Ross Beckman; Jin He; Christopher L Wolfgang; Elizabeth Thompson; Ralph H Hruban; Alison P Klein; Michael Goggins; Laura D Wood; Nicholas J Roberts Journal: Gastroenterology Date: 2019-02-01 Impact factor: 22.682
Authors: Chunling Hu; Steven N Hart; William R Bamlet; Raymond M Moore; Kannabiran Nandakumar; Bruce W Eckloff; Yean K Lee; Gloria M Petersen; Robert R McWilliams; Fergus J Couch Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-10-19 Impact factor: 4.254
Authors: Sarah A Bannon; Maria F Montiel; Jennifer B Goldstein; Wenli Dong; Maureen E Mork; Ester Borras; Merve Hasanov; Gauri R Varadhachary; Anirban Maitra; Matthew H Katz; Lei Feng; Andrew Futreal; David R Fogelman; Eduardo Vilar; Florencia McAllister Journal: Cancer Prev Res (Phila) Date: 2018-10-01